Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20371661 | 0.86 | FFAR1 (0.37) | FFAR1 | |
| SCHEMBL21940571 | 0.85 | LRRK2 (0.39) | FFAR1 | |
| SCHEMBL25239415 | 0.84 | CYP1A2 (0.35) | FFAR1 | |
| SCHEMBL21819814 | 0.82 | FFAR1 (0.35) | FFAR1 | |
| SCHEMBL22405990 | 0.81 | FFAR1 (0.34) | FFAR1 | |
| SCHEMBL15730539 | 0.81 | FFAR1 (0.33) | FFAR1 | |
| SCHEMBL20606960 | 0.80 | FFAR1 (0.36) | FFAR1 | |
| SCHEMBL26250779 | 0.79 | KLKB1 (0.43) | — | |
| SCHEMBL30062310 | 0.79 | LIPE (0.37) | FFAR1 | |
| SCHEMBL26254927 | 0.79 | KLKB1 (0.37) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | FFAR1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.